Actively Recruiting
Prevalence and Genetic Alternation of Autoimmune Polyglandular Syndrome Type II in Taiwan
Led by National Taiwan University Hospital · Updated on 2022-10-13
650
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Autoimmune polyendocrine syndrome (APS) is an autoimmune disease involving at least two endocrine organ. It is classified into type I and type II diseases. Among them, APS type II is more common. It is diagnosed when two of the three following diseases are diagnosed in the same patient, including type 1 diabetes mellitus, autoimmune thyroid disease, and primary adrenal insufficiency. In this study, we will observe the epidemiology, clinical characteristics, and genetic variants of APS II in Taiwan.
CONDITIONS
Official Title
Prevalence and Genetic Alternation of Autoimmune Polyglandular Syndrome Type II in Taiwan
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who visited NTUH during 2006 to 2021
- Patients diagnosed with at least two of the following: type 1 diabetes mellitus, primary adrenal insufficiency, and autoimmune thyroid disease
You will not qualify if you...
- Patients younger than 20 years old
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan, 100
Actively Recruiting
Research Team
S
Shyang-Rong Shih, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here